Huiyu Pharmaceuticals announced that the company and its wholly-owned subsidiary Huiyu Haiyue recently received the "Pharmaceutical Registration Certificate" approved and issued by the National Medical Products Administration, including the injectable aminophosphine and morinidazole sodium chloride injection. The original research for the injectable aminophosphine has not been marketed domestically, and currently, five companies hold the pharmaceutical approval for this drug, among which only Kaifeng Mingren and Huiyu Haiyue have passed or are deemed to have passed the consistency evaluation of generic drug quality and efficacy. The original research for the morinidazole sodium chloride injection is Jiangsu Haisun Pharmaceutical, and the company is the first generic pharmaceutical enterprise in the country, as well as the first to be deemed to have passed the consistency evaluation of generic drug quality and efficacy. The registration classifications for the two drugs are categorized as chemical drugs class 3 and 4, respectively, and are deemed to have passed the consistency evaluation of generic drug quality and efficacy after approval. The company has undertaken preliminary preparations for the marketing and sales of the products; however, there is significant uncertainty regarding whether substantial revenue can be generated in the future.